Eva Ciruelos, MD, PhD, University Hospital October 12, Madrid, Spain, discusses the latest developments in triple-negative breast cancer (TNBC), including the need for more biomarkers. BRCA mutations and PD-L1 are the only two biomarkers available, which can guide patients towards PARP inhibitors and immunotherapy respectively. Dr Ciruelos additionally highlights the emerging role of sacituzumab govitecan in this setting. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
